SABCS 2022 Conference Coverage
Playback speed
10 seconds
SABCS 2022 Results From a Pre-Planned monarchE OS Interim Analysis, Including 4-Year Efficacy Outcomes: Abemaciclib + ET for HR+/HER2-/N+ High-Risk EBC
By
SABCS 2022 Conference Coverage
FEATURING
Jens Huober
By
SABCS 2022 Conference Coverage
FEATURING
Jens Huober
272 views
January 30, 2023
Login to view comments.
Click here to Login
Videos